Technical Analysis for ZLAB - Zai Lab Limited

Grade Last Price % Change Price Change
grade D 15.95 1.59% 0.25
ZLAB closed up 1.59 percent on Monday, October 15, 2018, on 28 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ZLAB trend table...

Date Alert Name Type % Chg
Oct 15 Lower Bollinger Band Walk Weakness 0.00%
Oct 15 Inside Day Range Contraction 0.00%
Oct 15 Wide Bands Range Expansion 0.00%
Oct 15 Oversold Stochastic Weakness 0.00%
Oct 12 Slingshot Bearish Bearish Swing Setup 1.59%
Oct 12 Lower Bollinger Band Walk Weakness 1.59%
Oct 12 Wide Bands Range Expansion 1.59%
Oct 12 Lower Bollinger Band Touch Weakness 1.59%
Oct 12 Oversold Stochastic Weakness 1.59%
Oct 11 New 52 Week Closing Low Bearish 6.69%

Older signals for ZLAB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Is ZLAB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 12 The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Oct 10 Cancer Research Highlight: Five Prime Moves To Prime Time With A New Phase 3 Trial Off The Ground
Oct 1 Dosing underway in late-stage study of Five Prime's bemarituzumab in gastric cancer
Oct 1 Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Sep 27 Zai Lab appoints Tao Fu as President & Chief Operating Officer
Sep 27 Chinese Market Opportunity Could Drive Zai Lab’s Revenue Growth
Sep 27 Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence
Sep 26 Zai Lab's ZL-2301 shows encouraging action in mid-stage liver cancer study
Sep 26 Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Sep 26 Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
See more ZLAB news...
Indicators
Indicator Value
52 Week High 31.12
52 Week Low 14.29
Average Volume 277,046
200-Day Moving Average 21.7246
50-Day Moving Average 20.0954
20-Day Moving Average 18.348
10-Day Moving Average 17.431
Average True Range 1.002
ADX 28.98
+DI 11.9137
-DI 35.1029
Chandelier Exit (Long, 3 ATRs ) 17.004
Chandelier Exit (Short, 3 ATRs ) 17.296
Upper Bollinger Band 21.3753
Lower Bollinger Band 15.3207
Percent B (%b) 0.1
BandWidth 32.998692
MACD Line -1.1492
MACD Signal Line -0.8548
MACD Histogram -0.2944
Fundamentals Value
Market Cap 783.55 Million
Num Shares 49.1 Million
EPS -4.94
Price-to-Earnings (P/E) Ratio -3.23
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.94
Resistance 3 (R3) 16.92 16.58 16.78
Resistance 2 (R2) 16.58 16.32 16.59 16.72
Resistance 1 (R1) 16.26 16.17 16.42 16.28 16.66
Pivot Point 15.92 15.92 16.00 15.93 15.92
Support 1 (S1) 15.60 15.66 15.76 15.62 15.24
Support 2 (S2) 15.26 15.51 15.27 15.18
Support 3 (S3) 14.94 15.26 15.13
Support 4 (S4) 14.96